

EHA-SWG Annual Report EHA Lymphoma Group 2017

1. Name of the SWG: EHA Lymphoma Group
2. Focus and mission of the SWG (this section will be published also as SWG short presentation on the EHA website)

The EHA Lymphoma Group is a Scientific Working Group which was established in 2014.

Mission/vision of the EHA Lymphoma Group

To establish a network of scientists and hematologists covering all major areas of lymphoma research (including Hodgkin lymphoma, indolent and aggressive non-Hodgkin's lymphoma and Waldenström's macroglobulinemia), ultimately leading to:

- Improvement of the understanding of the pathogenesis/biology of lymphoma
- Improvement of the diagnostics in patients with lymphoma (including new imaging techniques and molecular characterization of lymphoma)
- Improvement of the (targeted) treatment of lymphoma
- Closer collaboration between lymphoma groups
- Optimal exchange and dissemination of knowledge and information; including improvement in education.

The EHA Lymphoma Group aims to become an organization that facilitates investigator-initiated, cross-border clinical trials and registry studies across different lymphoma subtypes, with a focus on rare types of lymphoma. In 2017 the EHA Lymphoma Group and the European Mantle Cell Network have merged. A closer collaboration with ELI, the European Lymphoma Institute is foreseen.

3. SWG highlights of past calendar year

1. The EHA LyG has had a yearly meeting in October 2017 in Lisbon, Portugal, organized and hosted by Maria Gomes da Silva. The meeting was attended by 24 persons representing the major lymphoma groups. This meeting was used to discuss the aims of the group and possibilities for collaboration in clinical trials and registries.
2. A scientific session was organized at EHA 2017 ('Diagnostics in lymphoma'), which was attended by approximately 150 persons and which was very well received.
3. An EHA SWG Scientific meeting was organized: March 10th-12th, 2017 (3-day meeting on advances in biology and treatment of B cell malignancies, with a focus on rare lymphomas). This meeting was attended by more than 80 participants. An interactive format was chosen with a mix of state of the art lectures, interactive sessions and case presentations by young hematologists.

4. Chair and affiliations

Prof. Marie José Kersten, head, dept of Hematology, Academic Medical Center, Amsterdam
Prof. Martin Dreyling, University Hospital Munich, Germany

5. Board members

Prof. dr. Massimo Federico, member (Modena Cancer Center, University of Modena and Reggio Emilia/FIL (Federazione Italiano di Lynfoni), Italy)

Prof. dr. Igor Aurer, member (University Hospital Centre, Zagreb/University of Zagreb/KroHem (Croatian Society for Hematology), Croatia)

Prof. dr. John Radford, member (Christie Hospital, University of Manchester/NCRI-UK, England)

6. Conflicts of interest of the board:

M.J. Kersten has received research support from Celgene, Roche, Millennium/Takeda, and has received honoraria from Celgene, Roche, Kite Pharma, Gilead, Janssen, Novartis and Amgen.

M. Dreyling has received research support from Celgene, Janssen, Mundipharma, Roche, and has received honoraria from Bayer, Celgene, Gilead, Janssen, Roche, Mundipharma, Sandoz.

7. Membership and website

Membership of the EHA LyG is possible at two levels: at the level of national lymphoma groups and at the level of individuals: for the latter option membership is open to any physician, nurse or scientist working in the field of lymphoma and/or interested in lymphoma research. In April 2015, the EHA LyG website was launched (www.ehalyg.org or www.ehalymphomagroup.org), at which point official membership registration was started. A preliminary list with members who had applied before the launch of the website is attached (appendix C), as well as a list of members who have registered via the website (appendix D). All the national lymphoma groups in Europe have committed to membership of the EHA LyG at the lymphoma group level (appendix A). More active registration for membership will be pursued (action point for the board members).

8. List of scientific activities:

Scientific projects of the EHA Lymphoma Group:

- transformation of follicular lymphoma (M. Federico)
- task force for improvement of clinical care for and research of elderly/frail patients with lymphoma, including initiation of a web-based international registry for elderly/frail patients (S. Luminari, M. Trneny, M. Federico) and the writing of a position paper on the subject
- HIV-related lymphoma (M. Hentrich)
- marginal zone lymphoma (C. Thieblemont/E. Zucca)
- the role of interim PET in DLBCL (J. Zijlstra)
- validation of a predictive model for thrombosis in patients with lymphoma (D. Antic)
- treatment of Burkitt and DH lymphoma (M. Chamuleau)

9. List of publications from or related to the SWG: No publications in 2017

Appendix A: participating European Lymphoma Groups:

Germany

GLSG (German Low Grade Lymphoma Study Group):
GHLSG (German High grade Lymphoma Study Group)
GHSg (German Hodgkin Study Group)
StIL (Studiengruppe Indolente Lymphomen)

France

LySA (The Lymphoma Study Organization)

Italy

FIL (Fondazione Italiana di Linfomi)

The Netherlands

HOVON lymphoma group

Spain

GOTEL
GELTAMO

Portugal

Portuguese Lymphoma Group

Austria

AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)

Switzerland

SAKK (Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung)

Nordic countries

NLG (Nordic Lymphoma Group)

Turkey

Turkish Hematology Association Scientific Subcommittee for Lymphoma

Croatia

KroHem

Czech Republic

Czech Lymphoma Study Group

Poland

PLRG (Polish Lymphoma Research Group)

Serbia

Serbian Lymphoma Group